NGM Biopharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing the next generation of medicines for the treatment of serious diseases. Our experienced scientific team has joined forces with an impressive group of industry professionals, Nobel Laureates and other distinguished researchers to build a company where innovation and cutting-edge science has provided the foundation for a robust drug discovery engine that has a track record of generating one new IND candidate per year. NGM’s current pipeline of clinical-stage programs consists of five drug candidates targeting liver and metabolic diseases, retinal diseases and cancer. The most advanced drug candidate, aldafermin (NGM282), is in Phase 2b clinical studies in non-alcoholic steatohepatitis (NASH) and is wholly-owned by NGM. Another drug candidate, NGM621, is in a Phase 2 study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). NGM’s strategic collaboration with Merck, with a current term running to March 2022, provides us with the resources and flexibility to pursue our ambitious R&D goals and further extend our pipeline of novel drug candidates.
We are seeking an experienced nonclinical project toxicologist to work in a team-based environment and join new and ongoing project teams. The candidate will serve as the nonclinical toxicologist working across discovery and development teams in a variety of disease areas. nonclinical toxicology and investigational safety studies at different stages of development, including exploratory, pilot, and pivotal studies. The toxicologist will review protocols, data, and study reports ensuring accurate presentation and interpretation of data in the context of the literature and project goals and contribute to regulatory documents to support global filings. Qualified Toxicologists will present results to project team and department meetings. Strong candidates will exhibit the ability to manage multiple projects simultaneously, and possess a basic understanding of regulatory guidance impacting drug development. Knowledge and understanding of GLPs and of regulatory requirements, including ICH requirements and other regional requirements, is also strongly desired.